Physician profile
Wayne Thomas Richey
NPI 1073508115
$5,012.04
in general payments reported to CMS, 2019-2025
31 companies · $1,126 in 2025
The $1,126 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $257 · 2020: $231 · 2021: $645 · 2022: $745 · 2023: $818 · 2024: $1,190 · 2025: $1,126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,133.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,234.40 | 2021-2025 | |
| Novo Nordisk INC | $469.31 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $429.87 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $355.58 | 2019-2025 | |
| Glaxosmithkline, LLC. | $321.11 | 2020-2025 | Trelegy Ellipta, Arexvy |
| Boston Scientific Corporation | $289.54 | 2025 | Watchman Flx, Cds - Mct/Cem Monitoring, Bodyguardian |
| Lilly USA, LLC | $228.24 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Exact Sciences Corporation | $201.62 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $153.85 | 2020-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $135.60 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $132.09 | 2024-2025 | Voquezna |
| Astellas Pharma US INC | $108.06 | 2024-2025 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $101.05 | 2023-2024 | Caplyta |
| Xeris Pharmaceuticals, INC. | $96.57 | 2021-2024 | Gvoke Hypopen |
| Dexcom, INC. | $87.96 | 2023-2024 | Dexcom G6 Transmitter |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $73.79 | 2019-2024 | Yupelri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $68.85 | 2022-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $67.91 | 2019 | |
| Merck Sharp & Dohme LLC | $61.63 | 2020-2022 | |
| Axsome Therapeutics, INC. | $58.59 | 2024-2025 | Auvelity |
| Lundbeck LLC | $53.65 | 2023 | Rexulti |
| Esperion Therapeutics, INC. | $47.70 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $42.42 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $40.58 | 2021 | |
| Allergan, INC. | $36.27 | 2019-2020 | |
| Shire North American Group INC | $29.96 | 2019 | |
| Idorsia Pharmaceuticals US INC | $29.85 | 2023 | Quviviq |
| Almatica Pharma LLC | $15.85 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.80 | 2022 | |
| Arbor Pharmaceuticals, INC. | $12.96 | 2019 | |
| Eisai INC. | $12.38 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wayne Richey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.